Tag: Mirikizumab

According to the Crohn's & Colitis Foundation, more than a million people in the United States live with ulcerative colitis (UC), but despite significant medical progress, there is no single **miracle drug for ulcerative colitis** that works for everyone. The best treatment depends on the individual, and recent breakthroughs have focused on a range of highly effective and targeted therapies.

In October 2023, the U.S. Food and Drug Administration (FDA) approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active ulcerative colitis in adults. Understanding what class of drug is mirikizumab reveals its targeted approach to treating inflammatory bowel diseases (IBD) by inhibiting a key pathway responsible for chronic inflammation.